These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 1347102)

  • 1. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.
    Ehrenforth S; Kreuz W; Scharrer I; Linde R; Funk M; Güngör T; Krackhardt B; Kornhuber B
    Lancet; 1992 Mar; 339(8793):594-8. PubMed ID: 1347102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey.
    Knobe KE; Sjörin E; Tengborn LI; Petrini P; Ljung RC
    Acta Paediatr; 2002; 91(8):910-4. PubMed ID: 12222714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitor development in haemophiliacs: theoretical background and clinical aspects.
    Sultan Y
    Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S55-7. PubMed ID: 7495970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune tolerance in children with factors VIII and IX inhibitors: a single centre experience.
    Mathias M; Liesner R; Hann I; Khair K
    Haemophilia; 2005 Jul; 11(4):340-5. PubMed ID: 16011585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.
    Kraiem I; Hadhri S; El Omri H; Sassi R; Chaabani W; Ennabli S; Skouri H
    Ann Biol Clin (Paris); 2012; 70(6):659-65. PubMed ID: 23207810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Risk of the appearance of inhibitors linked to the administration of factors VIII and IX. Review of the literature].
    Calvez T; Costagliola D
    Transfus Clin Biol; 1994; 1(6):427-35. PubMed ID: 7881588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
    Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).
    Hay CR; Baglin TP; Collins PW; Hill FG; Keeling DM
    Br J Haematol; 2000 Oct; 111(1):78-90. PubMed ID: 11091185
    [No Abstract]   [Full Text] [Related]  

  • 10. The economic impact of factor VIII inhibitors in patients with haemophilia.
    Bohn RL; Aledort LM; Putnam KG; Ewenstein BM; Mogun H; Avorn J
    Haemophilia; 2004 Jan; 10(1):63-8. PubMed ID: 14962222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product.
    Yee TT; Williams MD; Hill FG; Lee CA; Pasi KJ
    Thromb Haemost; 1997 Sep; 78(3):1027-9. PubMed ID: 9308748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
    Borhany M; Kumari M; Shamsi T; Naz A; Farzana T
    J Coll Physicians Surg Pak; 2012 May; 22(5):289-93. PubMed ID: 22538032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).
    Chitlur M; Warrier I; Rajpurkar M; Lusher JM
    Haemophilia; 2009 Sep; 15(5):1027-31. PubMed ID: 19515028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
    Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FVIII and FIX inhibitors in people living with hemophilia in Cameroon, Africa: a preliminary study.
    Balôgôg PN; Tagny CT; Ndoumba A; Mbanya D
    Int J Lab Hematol; 2014 Oct; 36(5):566-70. PubMed ID: 25356499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX.
    Nilsson IM; Hedner U
    Scand J Haematol; 1976 May; 16(5):369-82. PubMed ID: 951577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age.
    Lorenzo JI; López A; Altisent C; Aznar JA
    Br J Haematol; 2001 Jun; 113(3):600-3. PubMed ID: 11380444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of inhibitors in haemophilia. Ongoing epidemiological study.
    Serban M; Mihailov D; Pop L; Ionita H; Ursu E; Talpos-Niculescu S; Ritli L; Baghiu D; Uscatescu V; Petrovanu C; Stancu P; Savescu D; Cucuianu A; Schramm W
    Hamostaseologie; 2011 Nov; 31 Suppl 1():S20-3. PubMed ID: 22057218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of inhibitor development in severe haemophilia A children treated with cryoprecipitate and low-dose immune tolerance induction.
    ElAlfy MS; Tantawy AA; Ahmed MH; Abdin IA
    Haemophilia; 2000 Nov; 6(6):635-8. PubMed ID: 11122388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
    Addiego J; Kasper C; Abildgaard C; Hilgartner M; Lusher J; Glader B; Aledort L
    Lancet; 1993 Aug; 342(8869):462-4. PubMed ID: 8102429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.